Evidence map›Paper›PMID 33158717›Full record

Trial reportPhytomedicine : international journal of phytotherapy and phytopharmacology2021

Shufeng Jiedu, a promising herbal therapy for moderate COVID-19:Antiviral and anti-inflammatory properties, pathways of bioactive compounds, and a clinical real-world pragmatic study.

Lu Xia, Yujing Shi, Jie Su, Thomas Friedemann, Zhenggang Tao, Yunfei Lu, Yun Ling, Ying Lv, Ronghua Zhao, Zihan Geng and 3 more

Open access · hybridAbstract readPragmatic Clinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Phytomedicine : international journal of phytotherapy and phytopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 4 pooled it
15.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 4 syntheses or guidelines pooled it, 91 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Lu XiaShanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, P.R. China. Electronic address: hello0410@126.com.
Yujing ShiInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100025, P.R. China. Electronic address: yjshi@icmm.ac.cn.
Jie SuShanghai Institute for Advanced Immunochemical Studies, Shanghai Tech University, Shanghai, 201210, P.R. China. Electronic address: Sujie@shanghaitech.edu.cn.
Thomas FriedemannHanseMerkur Center for Traditional Chinese Medicine at the University Medical Center, Hamburg-Eppendorf, Hamburg, 20251, Germany. Electronic address: Friedemann@tcm-am-uke.de.
Zhenggang TaoEmergency Department, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.
Yunfei LuShanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, P.R. China.
Yun LingShanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, P.R. China.
Ying LvShanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, P.R. China.
Ronghua ZhaoInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100025, P.R. China.
Zihan GengInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100025, P.R. China.
Xiaolan CuiInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100025, P.R. China. Electronic address: xlcui@icmm.ac.cn.
Hongzhou LuShanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, P.R. China.
Sven SchröderHanseMerkur Center for Traditional Chinese Medicine at the University Medical Center, Hamburg-Eppendorf, Hamburg, 20251, Germany. Electronic address: Schroeder@tcm-am-uke.de.
Shanghai Public Health Clinical Center · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNUniversität Hamburg · DEShanghaiTech University · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundShufeng Jiedu capsules (SFJDC), a patented herbal drug composed of eight medicinal plants, is used for the treatment of different viral respiratory tract infectious diseases. Based on its antiviral, anti-inflammatory and immunoregulatory activity in acute lung injury, SFJDC might be a promising candidate for the treatment of COVID-19. PURPOSE: To evaluate the antiviral and anti-inflammatory properties and to discover the mechanism of action of SFJDC as a potential drug for the treatment of COVID-19. Furthermore, the study should determine the clinical effectiveness of SFJDC for the treatment of COVID-19.

designWe analyzed the antiviral and anti-inflammatory effects of SFJDC in a HCoV-229E mouse model on lung index, virus load in the lung, the release of cytokines, and on T- and B-lymphocytes. The mechanism of action was further investigated by network analysis. Additionally, we investigated data from a clinical pragmatic real-world study for patients with confirmed COVID-19, to evaluate the clinical effect of SFJDC and to determine the best time to start the treatment.

resultsSFJDC significantly reduced the virus load in the lung of HCoV-229E mice (from 1109.29 ± 696.75 to 0 ± 0 copies/ml), decreased inflammatory factors IL-6, IL-10, TNF-α, and IFN-γ in the lung, and increased the amount of CD4

conclusionSFJDC might be a promising drug for the treatment of COVID-19, but large-scale randomized, double-blinded, placebo-controlled clinical trials are needed to complement the real-world evidence. It might be beneficial to start SFJDC treatment as early as possible in suspected cases of COVID-19.

Indexed as

COVID-19 Drug TreatmentAdultAnimalsAnti-Inflammatory AgentsAntiviral AgentsCoronavirus 229E, HumanCoronavirus 3C ProteasesDrug CombinationsDrugs, Chinese HerbalFemaleHumansIndolesLopinavirLungMaleMice3C-like protease, SARS coronavirusAnti-Inflammatory AgentsAntiviral AgentsCoronavirus 3C ProteasesDrug CombinationsDrugs, Chinese HerbalIndolesLopinavirlopinavir-ritonavir drug combinationNF-kappa BRitonavirshufeng jieduSulfidesumifenovirAntiviralCOVID-19ImmunomodulationInflammationM(pro)PneumoniaSARS-CoV-2Shufeng Jiedu

Identifiers

PMID33158717
PMCPMC7581328
OpenAlexW3094152374

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.